Kirk Taylor, Md Email and Phone Number
Kirk Taylor, Md work email
- Valid
- Valid
Kirk Taylor, Md personal email
- Valid
As an accomplished medical and strategic leader, I have held high-profile roles within pharmaceutical, biotech, and disruptive startup companies. Combined with my clinical knowledge, I apply my entrepreneurial vision to drive the advancement of global life sciences companies. I have also led nascent startup companies to secure seed funding (Series A, B, and C) and execute initial public offerings. Known for being a confident and compelling communicator, I am asked to speak at internal meetings as well as industry conferences on Late Phase Development, Health Equity, Real World Evidence, and DEI. I have a demonstrated history of empowering and inspiring teams to perform to their fullest potential. People are a team's greatest asset. A neurologist by training, I have devoted my career to advancing technologies and therapies that address unmet medical need, improve patient outcomes and deliver on revenue and profitability goals. I most recently served as CMO and now advisor to Brainstorm Cell Therapeutics, a late stage ALS start up company with a product in Phase 3b. Some of the critical accomplishments of my career include the following: • Launched 3 new treatments for oncology (Copiktra, ,Bavencio, Tepotinib), 4 in multiple sclerosis, Lyrica for pain and fibromyalgia, Relpax for migraine, and Macugen for AMD• Presented safety data at FDA Advisory Committee Meeting for NurOwn ALS NDA review• Devised and executed the medical launch strategy for Copiktra, which treats chronic lymphocytic leukemia, small lymphocytic leukemia [CLL/SLL] and follicular lymphoma at Verastem Oncology. • Executed the ASD Phase 1 program for asset CP101, including IND, protocol development, and contract research organization [CRO] selection at Finch Therapeutics.• Won the Pharmavoice 100 Executives Award for 2023 for Top 100 Pharma Executives in the US Key Strategic and Operational Skills:Drug Development & CommercializationBudget Planning & Financial StewardshipGlobal Regulatory Processes & PracticesBoard Member & C- Suite EngagementHealth Equity, ESG and DEI PrinciplesCorporate Transformation and CultureNow seeking board, advisory and consulting positions, I am poised to help guide a growing organization to its next level of excellence. If you would like to connect to on board, consulting, advisory or other opportunities, please contact me through LinkedIn.
Massachusetts Life Sciences Center
View-
President And CeoMassachusetts Life Sciences Center Oct 2024 - PresentWaltham, Massachusetts, Us
-
Chief Medical Officer, EvpBrainstorm Cell Therapeutics May 2023 - Oct 2024Kiryat Aryeh, Petach Tikva, Il• Serve as a member of the Exec Leadership team, contributing to clinical development strategy, regulatory approvals, and overall corporate strategy, including long term business model, M&A, business development strategy, and culture. • Lead global medical affairs function and launch activities, in collaboration with key other members of senior management, that maximizes product launches and post-approval efforts.• Develop and lead customer excellence plan including KTL’s• Provide strategic input and leadership in the path to payers• Oversee the development and optimization of clinical/patient services.• Provide input into clinical strategy for the company, including development goals and R&D portfolio strategy. • Ensure that Brainstorm’s medical and scientific activities and external engagements are patient-centric and comply with all medical, and legislative requirements in operating jurisdictions.• Lead the development and execution of scientific meeting plan and activities, including creating a strategic plan for scientific disclosures across the calendar year, seeking/coordinating input on goals/content for each conference. -
Senior Vice President, Regional Medical Affairs, North AmericaEmd Serono, Inc. Aug 2019 - May 2023Boston, Massachusetts, UsServe as executive and leader of medical team in strategy definition and execution for 4 therapeutic pillars: oncology, neurology / immunology, fertility, and endocrine with accountability for 120 staff. Deliver strategy, data generation, clinical insights, scientific communications, and people development across 4 pillars. Present at industry-sponsored events focused on access, health equity and medical affairs to ensure company’s scientific message is delivered in various forums. Manage $75M medical budget to support growth of $1.5B portfolio.Chair of the Global Healthcare Diversity, Inclusion, Community, Equity and Engagement Committee (DICE)Executive Sponsor for Leaders of Color, Black Leaders Network, North American Asian Network and Hispanic Organization LatinX Association Employee Resource GroupsMedical representative on US Country Council advising on risk and health protocols for Healthcare, Life Science and Electronics Sector, Core member of COVID Taskforce (2020-2022) -
Senior Vice President, Medical Affairs Strategy And OperationsVerastem Oncology Oct 2018 - Aug 2019Needham, Massachusetts, UsTransitioned into full-time role from consulting position to redesign organizational structure, build operating function, optimize medical science liaison [MSL] territories, and create external medical affairs lead and continuing medical education [CME] functions for this development-stage biopharmaceutical company. Optimized team’s technical skills and drove cross-functional collaboration to design strategies for current and new products. Led US and EU steering committee -
Chief Of Strategy & Late Phase DevelopmentFinch Therapeutics May 2018 - Oct 2018Partnered with senior leadership team for late phase development and portfolio management. Defined plan for filing and commercializing internal assets. Optimized KOL engagement and advocacy and evaluated MSL KPIs with regional directors -
Chief Medical OfficerFinch Therapeutics Jul 2017 - May 2018Led strategy and execution of clinical development programs in C. difficile infection and autism spectrum disorder [ASD]. Served as SME on all clinical and strategic efforts. Established productive culture subsequent to Crestovo / Finch merger.
-
Chief Medical OfficerSolvd Health (Formerly Prescient Medicine) Aug 2016 - Jun 2017Carlsbad, California, UsConceptualized and executed medical strategies on behalf of this healthcare testing and diagnostics services provider. Collaborated with Capital Blue, Abbott, and Cleveland Clinic to apply algorithms to clinical databases. Designed and executed clinical studies with Hershey Penn State Medical School, Caron Treatment Center, and Jefferson Hospital Neurosurgery Department. Trained and mentored staff. Led medical due diligence for joint ventures. -
Vice President, North America Medical AffairsSanofi-Genzyme Apr 2015 - Aug 2016Paris, France, FrDeveloped North America medical affairs strategy for multiple sclerosis, which included driving data generation, educating healthcare professionals, fostering innovation, and creating programs to address unmet medical need. Designed Phase IV strategy. Grew $1B franchise of Aubagio and Lemtrada in collaboration with commercial, clinical development, and market access. -
Head Of Medical Affairs And Commercial DevelopmentAlzheon, Inc. Sep 2014 - Apr 2015Framingham, Ma, UsPresented clinical development plans for Down syndrome and ALZ medical affairs strategy to board of directors. Attended investor presentations to raise capital for small startup company. -
Vice President, Global Medical Insights, Global MedicalBiogen Idec Mar 2014 - Aug 2014Cambridge, Ma, UsLed cross-functional team to create systematic approach to harvest, analyze, and disseminate medical insights from emerging markets, distributors, EU, and US. Managed efforts to collect information via advisory boards, publications, congresses, distributor markets, launch excellence, medical field excellence, and clinical research. Influenced strategic and tactical approach associated with development and in-line portfolio. -
Regional Vice President, Medical Affairs – Global Emerging Markets, Europe, UsBiogen 2011 - 2014Cambridge, Ma, UsAligned regional medical affairs departments in strategic and tactical plans on late stage and in-line products. Managed $120M budget and directed senior leaders in US and Europe. Partnered on brand strategy and launch preparation with regional commercial SVPs for emerging markets, Europe, and US. Promoted from US Vice President, Medical Affairs [2011-2012].
-
Senior Vp, Us MedicalActelion 2008 - 2010Basel, ChGrew, mentored, and lead a cross-functional medical department consisting of 50 FTE’s in 5 groups when I started to ~100 FTEs in 7 groups at the present time. Managed 8 direct reports. Ensured the department’s focus on supporting the commercialization of 4 in-line products during the change: Tracleer, Ventavis, IV Epoprostenol (PAH) and Zavesca (Gaucher’s disease)Owned allocation and management of a budget of $58.1 MM allocated across the 7 groups: Clinical Operations, Medical Affairs, Regulatory Affairs, Medical Communications, Patient Services, PAH Pathways and Medical Science Liaisons. This money included budgets for 13 clinical trials, advisory boards, Investigator Initiated Studies, DDMAC submissions, publications, Travel and Entertainment and compensationAligned and executed initiatives with the members of the Executive Leadership Team to drive the business: Commercial, Legal, Finance and Human Resources: e.g. gave presentations at sales force POA meetings, trained reports on leading Advisory Boards, articulated Actelion’s commitment to PAH at Pulmonary Hypertension Association Events, chaired urgent Review Committees, designed corporate policies, facilitated Investigator Meetings, co-lead drug recall due to faulty vialsPartnered with the US Clinical Development Regulatory, the US Safety and the US Phase II-IIIa Clinical Development groups in Cherry Hill, NJ on developing US initiatives: e.g. Phase IIIA/B clinical studies, the Risk Evaluation and Mitigation Strategy for Tracleer, KOL development, Dear HCP letters, safety reviewsRepresented the Medical Department’s position on the US President’s Executive Leadership Team as a direct report, providing strategic input and business planning: e.g. restructuring of organization, office space design, 2010 budget presentation to global team, press releasesCommunicated, aligned, and executed strategies with the Global HQ Medical Affairs team and the Global Clinical Development teams in Basel, Switzerland. -
Senior Vice President, Us Medical DepartmentActelion 2008 - 2010Basel, ChGrew, mentored, and led cross-functional medical department comprised of 50 staff in 5 groups to 100 full-time employees in 7 groups. Managed 8 direct reports and $58.1M budget. Ensured department’s focus on supporting commercialization of Tracleer, Ventavis, IV Epoprostenol [PAH] and Zavesca [Gaucher’s disease] in-line products. Partnered with US clinical development regulatory, US safety and US Phase II-IIIa clinical development groups on developing Phase IIIA/B clinical studies, risk evaluation and mitigation strategy for Tracleer, KOL development, dear HCP letters, and safety reviews.
-
Regional Medical Director, EuropePfizer 2004 - 2007New York, New York, UsAlign and Implement HQ Northern European strategy in Austria, Denmark, Finland, Ireland, Netherlands, Norway, Sweden and Switzerland; coach, represent and unify the 8 Country Medical Directors reporting to me into a cross-cultural, regional team; develop medical input to NER HQ Operating Plan; drive growth of new products for the in-line brands through medical and cross-functional initiatives, thus supporting the President of the Northern Region: ~$2B business; lead the development team to maximize the established brand Fragmin Phase IIIb registration protocol including MPA and MHRA scientific advice meetings (Oct 2007);
Kirk Taylor, Md Skills
Kirk Taylor, Md Education Details
-
Harvard UniversityEnglish Literature -
University Of California, San FranciscoPost-Doctorate
-
Albert Einstein College Of MedicineNeurology Residency
-
Suny Downstate Health Sciences UniversityDoctor Of Medicine - Md
-
Harvard Business School Executive Education
-
InseadExecutive Education
-
Stanford UniversityExecutive Education
Frequently Asked Questions about Kirk Taylor, Md
What company does Kirk Taylor, Md work for?
Kirk Taylor, Md works for Massachusetts Life Sciences Center
What is Kirk Taylor, Md's role at the current company?
Kirk Taylor, Md's current role is President and CEO MLSC/ Chief Medical Officer/ Board Member/ CNS, Oncology, Rare Disease Drug Development/ DEI Advisor/ Corporate Governance/ ELC.
What is Kirk Taylor, Md's email address?
Kirk Taylor, Md's email address is ki****@****ail.com
What schools did Kirk Taylor, Md attend?
Kirk Taylor, Md attended Harvard University, University Of California, San Francisco, Albert Einstein College Of Medicine, Suny Downstate Health Sciences University, Harvard Business School Executive Education, Insead, Stanford University.
What skills is Kirk Taylor, Md known for?
Kirk Taylor, Md has skills like Medical Affairs, Pharmaceutical Industry, Clinical Trials, Biotechnology, Clinical Development, Medicine, Clinical Research, Neurology, Oncology, Regulatory Affairs, Life Sciences, Drug Development.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial